Brii Bio presents ENSURE Phase 2 data at EASL 2026 supporting BRII-179 for hepatitis B control
May 28, 2026 | 18:49
Brii Bio has presented final results from its Phase 2 ENSURE study at the EASL Congress 2026, showing that the addition of elebsiran to standard therapy produced a higher functional cure rate for hepatitis B virus, reinforcing the potential of BRII-179 as a durable treatment option.
Latest News
Mobile Version